Allograft Fat

Dr. Regina Marie Fearmonti is a double board-certified plastic surgeon with more than 25 years of experience specializing in advanced aesthetic and reconstructive surgery. Fellowship-trained in breast surgical oncology and reconstructive microsurgery, she is recognized not only for her surgical expertise, but also for her role as an educator and clinical scientist in the rapidly evolving field of regenerative aesthetics. Dr. Fearmonti has been an early adopter and national leader in fat grafting technologies, contributing to the refinement of techniques that optimize safety, viability, and long-term outcomes.

Autologous fat transfer, or harvesting a patient’s own fat through liposuction and re-injecting it to restore volume, remains the gold standard for biocompatible, natural results. However, not all patients are ideal candidates, and even in optimal cases, variability in fat survival (reported 30-70%) can present limitations. In the wake of massive weightloss trends and GLP-1 medications, patients now have limited donor sites. This has led to the development of advanced adipose-derived allograft technologies designed to enhance predictability and expand treatment options.

Renuva® (allograft adipose matrix) is a widely utilized regenerative injectable derived from donated human fat that has been processed to remove cellular components while preserving the extracellular matrix.  Dr. Fearmonti has over eight years of experience with this product. Renuva has dozens of publications and strong scientific backing both its mechanism of action and longevity of results. This scaffold supports angiogenesis and adipogenesis, allowing the patient’s own body to gradually replace the matrix with living fat. Available in 1.5 and 3 cc aliquots, it is particularly effective for small-volume corrections, facial rejuvenation, and improvement of contour irregularities, including post-liposuction defects. Composed of 100% extracellular matrix that is super concentrated, it also functions as well as to boost or potentiate your own fat harvested by liposuction, possibly improving its viability or percentage take. 

Lipoderma® represents a next-generation structural adipose allograft, engineered to provide both immediate volumization and a regenerative framework for long-term tissue integration. Its enhanced structural properties allow for more controlled placement and contour precision, making it well suited for both facial and body applications where subtle definition and durability are essential. It Is currently available in 1.5 and 10 cc aliquots, making it ideal for injection in the face hands at small corrections in the body.  

Alloclae™ is among the newest innovations in this category of structural adipose allografts. Designed with advanced processing techniques, Alloclae preserves key architectural and biochemical components of adipose tissue, enabling it to function as both a volumizing agent and a biologically active scaffold. Clinically, Alloclae is particularly valuable in areas requiring more robust structural support, such as hip dips, cellulite deformities, and complex contour irregularities. Due with large particle size and other factors, it is currently only used in the body, not the face.  Available in 12.5 and 25 cc aliquots, it can provide large volume enhancement or replacement.  Its ability to integrate with host tissue while maintaining shape and consistency makes it a powerful tool for both primary aesthetic enhancement and revision procedures.

Dr. Fearmonti’s expertise lies in selecting and combining these modalities, autologous fat transfer, Renuva®, Lipoderma®, and Alloclae™, to create highly individualized treatment plans. Her deep understanding of tissue biology, graft behavior, and regenerative science allows her to deliver outcomes that are not only aesthetically refined, but also biologically sound and long-lasting. Through her commitment to innovation and education, she continues to set the standard in modern regenerative plastic surgery.